Repository logo
 

Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk

Published version
Peer-reviewed

Change log

Authors

Liu, Jingjing 
Prager - van der Smissen, Wendy J. C. 
Collée, J. Margriet 
Bolla, Manjeet K. 
Wang, Qin 

Abstract

Abstract: In breast cancer, high levels of homeobox protein Hox-B13 (HOXB13) have been associated with disease progression of ER-positive breast cancer patients and resistance to tamoxifen treatment. Since HOXB13 p.G84E is a prostate cancer risk allele, we evaluated the association between HOXB13 germline mutations and breast cancer risk in a previous study consisting of 3,270 familial non-BRCA1/2 breast cancer cases and 2,327 controls from the Netherlands. Although both recurrent HOXB13 mutations p.G84E and p.R217C were not associated with breast cancer risk, the risk estimation for p.R217C was not very precise. To provide more conclusive evidence regarding the role of HOXB13 in breast cancer susceptibility, we here evaluated the association between HOXB13 mutations and increased breast cancer risk within 81 studies of the international Breast Cancer Association Consortium containing 68,521 invasive breast cancer patients and 54,865 controls. Both HOXB13 p.G84E and p.R217C did not associate with the development of breast cancer in European women, neither in the overall analysis (OR = 1.035, 95% CI = 0.859–1.246, P = 0.718 and OR = 0.798, 95% CI = 0.482–1.322, P = 0.381 respectively), nor in specific high-risk subgroups or breast cancer subtypes. Thus, although involved in breast cancer progression, HOXB13 is not a material breast cancer susceptibility gene.

Description

Keywords

Article, /631/67, /631/208, /692/4028, /692/499, article

Journal Title

Scientific Reports

Conference Name

Journal ISSN

2045-2322

Volume Title

10

Publisher

Nature Publishing Group UK